410 related articles for article (PubMed ID: 11971122)
21. [Escalating immunomodulatory therapy of multiple sclerosis. 1st supplement: December 2000].
Multiple Sklerose-Therapie-Konsensus Gruppe (MSTKG)
Nervenarzt; 2001 Feb; 72(2):150-7. PubMed ID: 11256151
[TBL] [Abstract][Full Text] [Related]
22. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis.
Sørensen PS
J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763
[TBL] [Abstract][Full Text] [Related]
23. Effects of cohort selection on the results of cost-effectiveness analysis of disease-modifying drugs for relapsing-remitting multiple sclerosis.
Becker RV; Dembek C
J Manag Care Pharm; 2011 Jun; 17(5):377-81. PubMed ID: 21657808
[TBL] [Abstract][Full Text] [Related]
24. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
[TBL] [Abstract][Full Text] [Related]
25. Teriflunomide for multiple sclerosis.
He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
[TBL] [Abstract][Full Text] [Related]
26. Sequential maintenance treatment with glatiramer acetate after mitoxantrone is safe and can limit exposure to immunosuppression in very active, relapsing remitting multiple sclerosis.
Ramtahal J; Jacob A; Das K; Boggild M
J Neurol; 2006 Sep; 253(9):1160-4. PubMed ID: 16990994
[TBL] [Abstract][Full Text] [Related]
27. The combination of cyclophosphamide plus interferon beta as rescue therapy could be used to treat relapsing-remitting multiple sclerosis patients-- twenty-four months follow-up.
Reggio E; Nicoletti A; Fiorilla T; Politi G; Reggio A; Patti F
J Neurol; 2005 Oct; 252(10):1255-61. PubMed ID: 15940386
[TBL] [Abstract][Full Text] [Related]
28. Azathioprine and interferon beta(1a) in relapsing-remitting multiple sclerosis patients: increasing efficacy of combined treatment.
Lus G; Romano F; Scuotto A; Accardo C; Cotrufo R
Eur Neurol; 2004; 51(1):15-20. PubMed ID: 14631124
[TBL] [Abstract][Full Text] [Related]
29. Glatiramer acetate for the treatment of multiple sclerosis.
Wolinsky JS
Expert Opin Pharmacother; 2004 Apr; 5(4):875-91. PubMed ID: 15102570
[TBL] [Abstract][Full Text] [Related]
30. Comparative efficacy and acceptability of disease-modifying therapies in patients with relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis.
Li H; Hu F; Zhang Y; Li K
J Neurol; 2020 Dec; 267(12):3489-3498. PubMed ID: 31129710
[TBL] [Abstract][Full Text] [Related]
31. Current approved options for treating patients with multiple sclerosis.
Rizvi SA; Agius MA
Neurology; 2004 Dec; 63(12 Suppl 6):S8-14. PubMed ID: 15623672
[TBL] [Abstract][Full Text] [Related]
32. Interferon beta in relapsing-remitting multiple sclerosis. An eight years experience in a specialist multiple sclerosis centre.
Río J; Tintoré M; Nos C; Téllez N; Galán I; Montalban X
J Neurol; 2005 Jul; 252(7):795-800. PubMed ID: 15772741
[TBL] [Abstract][Full Text] [Related]
33. Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis.
Simpson D; Noble S; Perry C
CNS Drugs; 2002; 16(12):825-50. PubMed ID: 12421116
[TBL] [Abstract][Full Text] [Related]
34. History of modern multiple sclerosis therapy.
Lublin F
J Neurol; 2005 Sep; 252 Suppl 3():iii3-iii9. PubMed ID: 16170498
[TBL] [Abstract][Full Text] [Related]
35. Natalizumab for relapsing remitting multiple sclerosis.
Pucci E; Giuliani G; Solari A; Simi S; Minozzi S; Di Pietrantonj C; Galea I
Cochrane Database Syst Rev; 2011 Oct; (10):CD007621. PubMed ID: 21975773
[TBL] [Abstract][Full Text] [Related]
36. Interferon-beta 1b in the treatment of multiple sclerosis.
Río J; Montalban X
Expert Opin Pharmacother; 2005 Dec; 6(16):2877-86. PubMed ID: 16318438
[TBL] [Abstract][Full Text] [Related]
37. Cost of care according to disease-modifying therapy in Mexicans with relapsing-remitting multiple sclerosis.
Macías-Islas MA; Soria-Cedillo IF; Velazquez-Quintana M; Rivera VM; Baca-Muro VI; Lemus-Carmona EA; Chiquete E
Acta Neurol Belg; 2013 Dec; 113(4):415-20. PubMed ID: 23670405
[TBL] [Abstract][Full Text] [Related]
38. A network meta-analysis of randomized controlled trials for comparing the effectiveness and safety profile of treatments with marketing authorization for relapsing multiple sclerosis.
Hadjigeorgiou GM; Doxani C; Miligkos M; Ziakas P; Bakalos G; Papadimitriou D; Mprotsis T; Grigoriadis N; Zintzaras E
J Clin Pharm Ther; 2013 Dec; 38(6):433-9. PubMed ID: 23957759
[TBL] [Abstract][Full Text] [Related]
39. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
[TBL] [Abstract][Full Text] [Related]
40. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada.
Dorman E; Kansal AR; Sarda S
J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
